PRS-343 in HER2-Positive Solid Tumors
Recruiting at9 trial locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 1
Waitlist Available
Sponsor: Pieris Pharmaceuticals, Inc.
No Placebo Group
Trial Summary
What is the purpose of this trial?
A multi center, open-label, Phase 1 dose escalation study with expansion cohort is designed to determine the MTD, RP2D and dosing schedule of PRS-343 in patients with HER2+ advanced or metastatic solid tumors.
Research Team
Eligibility Criteria
Inclusion Criteria
Signed written informed consent obtained prior to performing any study procedure, including pre-screening and screening procedures.
Men and women ≥18 years.
Dose escalation: Histologically or cytologically confirmed diagnosis of unresectable/locally advanced and/or metastatic HER2+ solid tumor malignancy and for which standard therapies are not available, are no longer effective, are not tolerated, or have been declined by the patient.
See 7 more
Treatment Details
Interventions
- PRS-343 (Monoclonal Antibodies)
Participant Groups
1Treatment groups
Experimental Treatment
Group I: PRS-343Experimental Treatment1 Intervention
Find a Clinic Near You
Who Is Running the Clinical Trial?
Pieris Pharmaceuticals, Inc.
Lead Sponsor
Trials
4
Recruited
250+